Companies /Healthcare
Ocugen Inc
NASDAQ: OCGN Biotechnology
$0.83
▼ $0.05 (−5.24%) today
Markets closed · 1:47am ET

Ocugen (OCGN) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
43%
EPS beat rate
+4.71%
Avg. EPS surprise
Consecutive EPS beats
OCGN vs Market · 30-day return after each reportOCGNS&P 500
0%+30%+60%+73.1%+6.6%Q1 25+5.6%+3.5%Q2 25−14.9%+0.9%Q3 25−9.7%−3.8%Q4 25−14.1%+1.9%Q1 26+7.3%−0.3%Q2 26
0%+30%+60%Q1 25Q3 25Q1 26
OCGN EPS Trend · estimate vs actualEstimateActual
$-0.06$-0.03$-0.06$-0.05Q1 25$-0.06$-0.05Q2 25$-0.06$-0.07Q3 25$-0.06$-0.06Q4 25$-0.05$-0.06Q1 26$-0.05$-0.07Q2 26$-0.05$-0.01Q3 26
$-0.06$-0.03Q1 25Q3 25Q1 26Q3 26
OCGN Revenue Trend · estimate vs actualEstimateActual
$0$600,000$1.2M$1.8M$350,000$1.4MQ2 25$440,000$1.8MQ3 25$860,000$-193,000Q4 25$358,140$1.5MQ1 26$888,830$1.5MQ2 26$780,000$2.0MQ3 26
$0$600,000$1.2M$1.8MQ2 25Q4 25Q2 26

How Often Does Ocugen Beat Earnings Estimates?

Ocugen beat EPS estimates in 3 of its last 7 reported quarters.

OCGN quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 Includes a $16,562 thousand non-cash gain from the change in fair value of derivative liability (embedded derivative on convertible notes); interest expense rose to $3,090 thousand from $1,314 thousand. $-0.01 est. $-0.05 +81.24% $2.0M est. $780,000 +150.13%
Q2 2026 Includes $2.383 million loss on extinguishment of debt from retiring Avenue Capital loan and $1.891 million loss from change in fair value of derivative liability related to convertible notes $-0.07 est. $-0.05 −34.62% $1.5M est. $888,830 +67.41%
Q1 2026 $-0.06 est. $-0.05 −16.05% $1.5M est. $358,140 +328.04%
Q4 2025 $-0.06 est. $-0.06 −4.35% $-193,000 est. $860,000 −122.44%
Q3 2025 $-0.07 est. $-0.06 −21.74% $1.8M est. $440,000 +298.18%
Q2 2025 $-0.05 est. $-0.06 +11.82% $1.4M est. $350,000 +292.29%
Q1 2025 $-0.05 est. $-0.06 +16.67% $1.5M —

Figures from SEC filings and company reports. Not investment advice.